This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: Q22 (Congenital malformations of pulmonary and tricuspid valves) | Special Copayment Reduction: V192 (Special copayment reduction for heart disease: 5% copayment for up to 30 days from the registration date) |
| B. Synonyms | Pulmonary stenosis/atresia, Ebstein's anomaly, tricuspid stenosis/atresia, right heart hypoplasia, downward displacement of the tricuspid valve |
| C. Adult onset | Mild pulmonary stenosis and mild forms of Ebstein's anomaly may remain asymptomatic into adulthood and are sometimes first diagnosed through arrhythmia or right heart failure. |
| 1. History | Wilhelm Ebstein first described the malformation with downward displacement of the tricuspid valve in 1866; balloon dilation for pulmonary stenosis reported by Kan et al. in 1982 |
| 2. Causes | Pulmonary valve: abnormal semilunar valve formation (fusion, hypoplasia); Ebstein: failure of tricuspid myocardial delamination (delamination failure) |
| 3. Genetics | NKX2-5, GATA4, MYH6 variants; association of Ebstein's anomaly with lithium exposure and NKX2-5; Noonan syndrome (PTPN11) and pulmonary stenosis |
| 4. General epidemiology | Pulmonary stenosis 0.6–0.8/1,000 live births; Ebstein's anomaly 0.05–0.1/1,000 live births; tricuspid atresia 0.03–0.05/1,000 |
| 5. Pathophysiology | Abnormal formation of the pulmonary semilunar valve; failure of tricuspid delamination displaces the valve downward into the ventricle, causing atrialization of the right ventricle |
| 6. Symptoms | Pulmonary stenosis: mild and asymptomatic to severe cyanosis; Ebstein: cyanosis, palpitations, paroxysmal tachycardia, right heart failure |
| 7. Signs | Pulmonary stenosis: systolic ejection murmur at the upper left sternal border, pulmonary ejection click; Ebstein: widely split S1 and S2, tricuspid regurgitation murmur |
| 8. Screening | Prenatal fetal echocardiography, neonatal pulse oximetry, auscultation, chest X-ray, ECG |
| 9. Diagnosis | Transthoracic echocardiography (Doppler), cardiac MRI, cardiac catheterization (pulmonary artery pressure, oxygen saturation), electrophysiological study (accessory pathways in Ebstein) |
| 10. Treatment | Pulmonary stenosis: balloon pulmonary valvuloplasty (BPV); Ebstein: Cone repair or tricuspid valve replacement; tricuspid atresia: single-ventricle pathway |
| 11. Prognosis | 10-year restenosis rate after BPV for pulmonary stenosis 10–20%; good long-term survival after Cone repair for Ebstein, arrhythmia management needed |
| 12. Prevention | Avoiding lithium exposure during pregnancy (Ebstein risk), prenatal diagnosis, genetic counseling for Noonan syndrome |
| 13. References | Ebstein Anomaly and Malformation — StatPearls … and 9 other papers |
Medical description of congenital malformations of the pulmonary and tricuspid valves developed alongside advances in European pathology in the 18th–19th centuries. Pulmonary stenosis already appeared in Giovanni Morgagni's autopsy descriptions in 1761; he recorded the case of a patient with a thickened pulmonary valve and a dilated right ventricle. Its clinical importance was later highlighted when Fallot defined pulmonary stenosis as a core component of tetralogy of Fallot in 1888. Medical treatment of isolated pulmonary stenosis began when Brock succeeded with transventricular pulmonary valvotomy in 1953.
Ebstein's anomaly was named after the German physician Wilhelm Ebstein, who in 1866 first described, at the autopsy of a 19-year-old cyanotic man, a malformation in which the tricuspid valve was displaced downward into the right ventricle. Ebstein accurately explained that this malformation is characterized by abnormal intraventricular attachment of the tricuspid leaflets, atrialization of the right ventricle, and reduction of the functional right ventricle. This malformation was first diagnosed clinically in a living patient by Soloff et al. in 1951, and with subsequent advances in echocardiography noninvasive diagnosis became possible.
A therapeutic breakthrough came in 1982 when Kan et al. first reported percutaneous balloon pulmonary valvuloplasty (BPV). BPV quickly became established as the standard treatment for pulmonary stenosis, largely replacing open-heart surgery. Surgical correction of Ebstein's anomaly was first performed by Hunter and Lillehei in 1958, but when da Silva et al. at Mayo Clinic developed the Cone repair in 2007, a superior procedure achieving anatomical restoration of the tricuspid valve was established. Cone repair is now established as the standard procedure for patients with Ebstein's anomaly who have suitable anatomy.
The cause of Q22 group malformations is abnormality in the embryonic development of the right heart valves. Pulmonary valve stenosis (Q22.1) arises from abnormal development of the valve commissures or the leaflet tissue itself during formation of the three semilunar valve leaflets that make up the pulmonary valve. The most common form is the commissural fusion type, in which the three leaflets fuse at the commissures to form a dome, and bicuspid pulmonary valves and dysplastic pulmonary valves are not uncommon. Pulmonary valve atresia (Q22.0) is a serious form in which pulmonary blood flow is blocked by complete fusion or hypoplasia of the valve tissue.
The key developmental mechanism of Ebstein's anomaly (Q22.5) is failure of delamination during tricuspid valve formation. Normally, the tricuspid leaflets delaminate from the right ventricular myocardium early in development to form a pliable valve structure. If this process is incomplete, the leaflets remain attached to the ventricular wall and are displaced downward into the ventricle below the anatomical tricuspid annulus. The degree of displacement and the extent of right ventricular atrialization vary with the degree of delamination failure, which explains the phenotypic diversity of Ebstein's anomaly.
Tricuspid stenosis (Q22.4) and atresia (Q22.9) arise from abnormalities in atrioventricular septation and endocardial cushion development, and mostly appear as part of complex congenital heart malformations. Hypoplastic right heart syndrome (Q22.6) is a complex malformation with pulmonary valve atresia and atrial septal defect, characterized by right ventricular underdevelopment and tricuspid hypoplasia. As an environmental factor, lithium exposure in early pregnancy was considered a risk factor for Ebstein's anomaly, but recent meta-analyses have reassessed the absolute increase in risk as low.
The genetics of Q22 group malformations are heterogeneous and mostly follow multifactorial inheritance. Familial occurrence is not uncommon in Ebstein's anomaly, and NKX2-5 transcription factor variants have been reported to be associated with a combined phenotype of Ebstein's anomaly and atrioventricular conduction abnormalities. MYH6 (cardiac alpha-myosin heavy chain) variants have also been proposed to be associated with tricuspid valve malformations. Ebstein's anomaly mostly occurs sporadically, but its incidence among first-degree relatives is higher than in the general population, indicating a genetic predisposition.
Pulmonary stenosis is strongly associated with several syndromes. Noonan syndrome is an autosomal dominant syndrome caused by variants in the PTPN11 (about 50%), SOS1, RAF1, KRAS, and BRAF genes; pulmonary stenosis with valve dysplasia is its most common cardiac phenotype, occurring in about 50–60% of patients with Noonan syndrome. Dysplastic pulmonary stenosis responds poorly to balloon dilation and often requires surgical treatment. The association of Williams syndrome (7q11.23 deletion, ELN gene) with peripheral pulmonary artery stenosis is also well known. In Alagille syndrome (JAG1 variants), peripheral pulmonary artery stenosis is also a major cardiac finding.
In 22q11.2 deletion syndrome, pulmonary atresia and conotruncal malformations may coexist, and patients with tricuspid atresia are sometimes found to have chromosomal abnormalities (Down syndrome, other trisomies), so systematic chromosomal analysis and genetic counseling are recommended. Whole-exome analysis is also identifying de novo mutations in some patients with complex right heart valve malformations.
Among Q22 group malformations, pulmonary stenosis is the most frequent congenital heart disease. Pulmonary valve stenosis (Q22.1) accounts for about 8–10% of congenital heart disease, with an incidence of about 0.6–0.8 per 1,000 live births. Excluding tetralogy of Fallot (Q21.3), it is the third or fourth most common isolated malformation among congenital heart diseases. There is no or only a very small sex difference. Pulmonary valve atresia (Q22.0) is rare at about 0.7–1 per 10,000 live births, and its hemodynamics and prognosis differ greatly depending on whether a ventricular septal defect is present.
Ebstein's anomaly (Q22.5) accounts for about 0.5% of congenital heart disease, with an incidence of about 0.05–0.1 per 1,000 live births. There is no sex difference. The spectrum of clinical phenotypes is very broad, ranging from cases diagnosed with severe heart failure in the neonatal period to mild forms found incidentally in adulthood. Tricuspid atresia (including Q22.9) is the third most common cyanotic congenital heart disease after tetralogy of Fallot and D-TGA, with a frequency of about 0.3–0.5 per 10,000 live births. Hypoplastic right heart syndrome (Q22.6) occurs in about 0.5–0.8 per 10,000 live births and is a complex malformation presenting in a critical state in the neonatal period.
The pathophysiology of pulmonary valve stenosis begins with conotruncal separation of the primitive heart tube in the embryo. The pulmonary valve develops as three semilunar cusp primordia (cushions) form on the pulmonary side of the conotruncus. In this process, unequal growth or premature fusion of the three valve primordia, or excessive myxomatous change of the valve tissue, causes commissural fusion–type pulmonary stenosis. In dysplastic pulmonary stenosis, the leaflet tissue is thick, myxomatous, and inflexible, and cannot form a dome. Dysplastic pulmonary stenosis in Noonan syndrome is explained by a mechanism in which Ras-MAPK pathway hyperactivation due to PTPN11 variants induces abnormal proliferation and differentiation of valve interstitial cells.
The key developmental mechanism of Ebstein's anomaly is abnormal tricuspid delamination. In normal development, the tricuspid leaflets delaminate from the right ventricular myocardial tissue at 5–8 weeks of gestation to form independent leaflet structures. If delamination is incomplete, the posterior leaflet and septal leaflet remain attached to the myocardium and are displaced from the tricuspid annulus toward the ventricle. Depending on the degree of displacement, part of the right ventricle becomes functionally atrialized, reducing the true right ventricular volume, and tricuspid regurgitation develops. If an atrial septal defect or patent foramen ovale is present, a right-to-left shunt develops and cyanosis appears.
Clinical symptoms of pulmonary stenosis are classified by severity as mild (pressure gradient <36 mmHg), moderate (36–64 mmHg), and severe (≥64 mmHg). Mild pulmonary stenosis is mostly asymptomatic and found incidentally through a murmur. In moderate stenosis, exertional dyspnea, fatigue, and dizziness may occur. In severe stenosis, cyanosis and heart failure symptoms develop even at rest, and it may present in the neonatal period as a critical form requiring ductus-dependent pulmonary blood flow.
Symptoms of Ebstein's anomaly vary greatly with the degree of tricuspid displacement, severity of tricuspid regurgitation, right ventricular function, and associated malformations. Severe forms presenting in the neonatal period require immediate intensive care for severe cyanosis, dyspnea, and right heart failure. In mild forms first diagnosed in adulthood, the main symptoms are palpitations (paroxysmal supraventricular tachycardia, WPW tachycardia due to Wolff-Parkinson-White syndrome), reduced exercise capacity, and mild cyanosis. WPW syndrome accompanies about 10–25% of Ebstein's anomaly, and when atrial fibrillation or flutter occurs, a rapid ventricular response can trigger dangerous arrhythmias.
The most characteristic auscultatory finding of pulmonary stenosis is a systolic ejection murmur heard at the upper left sternal border (2nd intercostal space); the more severe the stenosis, the longer the murmur and the later its peak intensity. In valvular (dome-shaped) stenosis, a systolic ejection click whose intensity decreases on inspiration precedes the systolic murmur. The pulmonary component of the second heart sound (P2) diminishes or disappears depending on the severity of stenosis. On chest X-ray, decreased pulmonary vascularity (reduced pulmonary blood flow) and prominence of the main pulmonary artery due to poststenotic dilation may be observed.
The auscultatory finding of Ebstein's anomaly is characteristically a holosystolic murmur due to tricuspid regurgitation heard at the lower left sternal border, and the first and second heart sounds are widely split so that a triple or quadruple rhythm may be heard. With cyanosis, clubbing of the fingers and toes is observed. On ECG, right bundle branch block (RBBB), delta waves (with WPW syndrome), tall peaked P waves (P pulmonale due to a giant right atrium), and right axis deviation are characteristic. Chest X-ray shows cardiomegaly (a 'balloon-shaped' heart, especially due to right atrial enlargement) and decreased pulmonary vascularity.
Screening for congenital malformations of the pulmonary and tricuspid valves takes place in two stages, prenatal and postnatal. Prenatally, pulmonary valve stenosis/atresia, Ebstein's anomaly, and tricuspid atresia can be evaluated on detailed fetal echocardiography at 18–22 weeks of gestation. The prenatal detection rate of Ebstein's anomaly is reported at about 30–70% depending on technical expertise, and Doppler signals of tricuspid regurgitation and right atrial dilation are the main ultrasound findings.
In the neonatal period, pulse oximetry screening is important for early detection of pulmonary atresia and severe stenosis (which cause cyanosis). Detection of a murmur at the upper left sternal border on neonatal auscultation is the traditional tool for screening pulmonary stenosis. Chest X-ray evaluates pulmonary vascularity and heart size, and ECG helps detect right ventricular hypertrophy, right bundle branch block, or a WPW pattern. When Noonan syndrome or another syndrome is suspected, genetic testing should be performed early to establish a treatment plan anticipating dysplastic pulmonary stenosis.
Echocardiography is the primary tool for confirming Q22 group malformations. Transthoracic echocardiography (TTE) noninvasively evaluates the anatomical morphology of the pulmonary valve (bicuspid/tricuspid, presence of dysplasia), valve opening area, systolic pressure gradient (peak and mean) by Doppler measurement, right ventricular size and function, and degree of tricuspid regurgitation. In Ebstein's anomaly, the degree of tricuspid displacement (downward distance from the normal position), the proportion of right ventricular atrialization, functional right ventricular volume, and the presence of associated ASD/PFO are evaluated.
Cardiac MRI (CMR) is essential for quantitative evaluation of functional right ventricular volume and tricuspid regurgitant volume in Ebstein's anomaly and is used for preoperative anatomical assessment and postoperative follow-up. Cardiac catheterization is performed for direct measurement of the right ventricular–pulmonary artery pressure gradient, oxygen saturation measurement, calculation of pulmonary vascular resistance, and evaluation of indications for balloon dilation. Electrophysiological study (EPS) is used in Ebstein's anomaly to accurately diagnose WPW syndrome or other arrhythmias and to identify the location and characteristics of accessory pathways in order to plan catheter ablation.
Treatment of pulmonary stenosis is determined by the severity of stenosis and the anatomical morphology of the valve. For mild pulmonary stenosis (pressure gradient <40 mmHg), regular follow-up is sufficient if there is no cardiac dysfunction or symptoms. For moderate or greater stenosis (pressure gradient ≥40 mmHg) or symptomatic cases, percutaneous balloon pulmonary valvuloplasty (BPV) is the first-line treatment. BPV separates the fused commissures using a balloon catheter and is highly effective at immediately reducing the pressure gradient in the commissural fusion (dome-shaped) type (success rate 85–95%). Dysplastic pulmonary stenosis (associated with Noonan syndrome) responds poorly to BPV and requires surgical valvuloplasty or valve replacement.
Surgical indications for Ebstein's anomaly are symptoms (heart failure, cyanosis, reduced exercise capacity), severe tricuspid regurgitation, reduced functional right ventricular function, and paradoxical embolism. The current standard operation is the Cone repair, an anatomical correction that reconstructs the tricuspid annulus 360° using anterior leaflet tissue. When Cone repair is not possible, tricuspid valve replacement (bioprosthetic or mechanical) is performed. An associated WPW accessory pathway is treated with simultaneous intraoperative ablation of the accessory pathway or with catheter ablation before or after surgery. In tricuspid atresia, the right ventricle is functionally unusable, so the single-ventricle Fontan pathway is the final palliative treatment.
The long-term prognosis of appropriately treated pulmonary stenosis is very good. When an immediate reduction in pressure gradient is achieved after BPV, 10-year survival exceeds 95%, and a near-normal life is possible. However, restenosis develops during long-term follow-up in about 10–20%, and repeat intervention may be needed. In dysplastic pulmonary stenosis, residual stenosis may remain even after surgery, and pulmonary insufficiency develops as a long-term complication.
The natural course of Ebstein's anomaly differs greatly according to anatomical severity. Severe forms diagnosed in the fetal or neonatal period show high mortality, whereas mildly affected adult patients can enjoy a near-normal lifespan. In mid-term follow-up (5–10 years) after Cone repair, the proportion maintaining a functional right ventricle without recurrence of tricuspid regurgitation reaches 80–90%. Long-term complications include residual tricuspid regurgitation, arrhythmia (atrial fibrillation/flutter, WPW tachycardia), and right heart failure, which should be actively managed during regular follow-up. Pregnancy in adult patients with Ebstein's anomaly carries risks of worsening tricuspid regurgitation and increased arrhythmia, so specialist counseling before pregnancy is essential.
Absolute prevention of Q22 group congenital malformations is currently impossible, but outcomes can be improved through risk factor management and prenatal screening. When there is a family history of Noonan syndrome, disease risk should be assessed through genetic counseling and familial genetic testing such as PTPN11, and pulmonary stenosis should be diagnosed early through detailed fetal echocardiography during pregnancy. There are longstanding reports that lithium exposure during pregnancy is associated with an increased risk of Ebstein's anomaly; although recent studies have reassessed the absolute increase in risk as small, consultation between psychiatry and obstetrics specialists regarding lithium use for bipolar disorder treatment is recommended when planning pregnancy.
Checking rubella vaccination status in early pregnancy and controlling blood glucose before pregnancy in diabetic mothers lower the overall risk of congenital heart malformations. Early detection of right heart valve malformations through detailed prenatal fetal echocardiography enables planning of delivery, preparation for neonatal intensive care, and planning of immediate ductal maintenance therapy (prostaglandin E1 administration), greatly improving neonatal outcomes. When confirmed severe pulmonary atresia or Ebstein's anomaly is diagnosed prenatally, delivery at a specialized congenital heart center is recommended.
Attenhofer Jost CH, Connolly HM, Dearani JA, et al. Ebstein's anomaly. Circulation. 2007;115(2):277–285. DOI: 10.1161/CIRCULATIONAHA.106.619338. PMID: 17228014.
da Silva JP, da Silva LF. Ebstein's anomaly of the tricuspid valve: the cone repair. Pediatric Cardiac Surgery Annual. 2012;15(1):38–45. DOI: 10.1053/j.pcsu.2012.01.006. PMID: 22405080.
Kan JS, White RI Jr, Mitchell SE, et al. Percutaneous balloon valvuloplasty: a new method for treating congenital pulmonary-valve stenosis. New England Journal of Medicine. 1982;307(9):540–542. DOI: 10.1056/NEJM198208263070907. PMID: 7099141.
Donnelly JP, Brown JM, Radford DJ. Pregnancy outcome and Ebstein's anomaly. British Heart Journal. 1991;66(5):368–371. DOI: 10.1136/hrt.66.5.368. PMID: 1747296.
Sarkozy A, Digilio MC, Dallapiccola B. Cardio-facio-cutaneous syndrome and related conditions. Orphanet Journal of Rare Diseases. 2008;3:15. DOI: 10.1186/1750-1172-3-15. PMID: 18505575.
Holst KA, Connolly HM, Dearani JA. Ebstein's anomaly. Methodist DeBakey Cardiovascular Journal. 2019;15(2):138–144. DOI: 10.14797/mdcj-15-2-138. PMID: 31384388.
Warnes CA, Williams RG, Bashore TM, et al. ACC/AHA 2008 guidelines for the management of adults with congenital heart disease. Journal of the American College of Cardiology. 2008;52(23):e1–e121. DOI: 10.1016/j.jacc.2008.10.001. PMID: 19038677.
Baumgartner H, De Backer J, Babu-Narayan SV, et al. 2020 ESC Guidelines for the management of adult congenital heart disease. European Heart Journal. 2021;42(6):563–645. DOI: 10.1093/eurheartj/ehaa554. PMID: 32860028.
Gatzoulis MA, Freeman MA, Siu SC, et al. Atrial arrhythmia after surgical closure of atrial septal defects in adults. New England Journal of Medicine. 1999;340(11):839–846. DOI: 10.1056/NEJM199903183401103. PMID: 10080844.
Graham TP Jr, Driscoll DJ, Gersony WM, et al. Task force 2: congenital heart disease. Journal of the American College of Cardiology. 2005;45(8):1326–1333. DOI: 10.1016/j.jacc.2005.02.009. PMID: 15837278.